Sol-Gel Technologies (SLGL) Shares Outstanding (Weighted Average) (2016 - 2025)
Sol-Gel Technologies (SLGL) reported Shares Outstanding (Weighted Average) of $2.8 million for Q4 2025, little changed year-over-year from $2.8 million in Q4 2024, and little changed on a QoQ basis from $2.8 million in Q3 2025.
Sol-Gel Technologies (SLGL) has 10 years of Shares Outstanding (Weighted Average) data on file, last reported at $2.8 million in Q4 2025.
- Quarterly Shares Outstanding (Weighted Average) changed 0.0% year-over-year to $2.8 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $2.8 million (changed 0.0% YoY) and the FY2025 annual result came in at $2.8 million, changed 0.0% from the prior year.
- Shares Outstanding (Weighted Average) held at $2.8 million in Q4 2025 per SLGL's latest filing, from $2.8 million in the prior quarter.
- Across five years, Shares Outstanding (Weighted Average) topped out at $27.9 million in Q1 2024 and bottomed at $2.3 million in Q4 2022.
- The 5-year median for Shares Outstanding (Weighted Average) is $23.0 million (2021), against an average of $16.7 million.
- The widest annual swing landed in 2023, when Shares Outstanding (Weighted Average) grew 19.59%; it then slumped 90.0% in 2024.
- Tracing SLGL's Shares Outstanding (Weighted Average) over 5 years: stood at $23.1 million in 2021, then plunged by 89.97% to $2.3 million in 2022, then grew by 17.11% to $2.7 million in 2023, then climbed by 2.85% to $2.8 million in 2024, then increased by 0.0% to $2.8 million in 2025.
- Per Business Quant, the three latest SLGL Shares Outstanding (Weighted Average) figures stand at $2.8 million (Q4 2025), $2.8 million (Q3 2025), and $2.8 million (Q4 2024).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares (Weighted Avg.) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | 177,333.76 Bn |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | 185,491.37 Bn |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 100.00 Bn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | 55.66 Bn |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | 118.76 Bn |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 254.10 Mn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | 16.04 Bn |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 104.00 Mn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 132.89 Mn |
| 10 | Sol-Gel Technologies | 205.76 Mn | 194.73 Mn | - | 2.79 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 2.79 Mn |
| Sep 30, 2025 | 2.79 Mn |
| Dec 31, 2024 | 2.79 Mn |
| Sep 30, 2024 | 2.79 Mn |
| Jun 30, 2024 | 27.86 Mn |
| Mar 31, 2024 | 27.86 Mn |
| Dec 31, 2023 | 2.71 Mn |
| Sep 30, 2023 | 27.84 Mn |
| Jun 30, 2023 | 27.66 Mn |
| Mar 31, 2023 | 24.94 Mn |
| Dec 31, 2022 | 2.31 Mn |
| Jun 30, 2022 | 23.13 Mn |
| Mar 31, 2022 | 23.13 Mn |
| Dec 31, 2021 | 23.06 Mn |
| Jun 30, 2021 | 23.03 Mn |
| Mar 31, 2021 | 23.00 Mn |
| Dec 31, 2020 | 22.57 Mn |
| Sep 30, 2020 | 23.00 Mn |
| Jun 30, 2020 | 22.92 Mn |
| Mar 31, 2020 | 21.36 Mn |
| Dec 31, 2019 | 19.53 Mn |
| Sep 30, 2019 | 19.79 Mn |
| Jun 30, 2019 | 18.95 Mn |
| Mar 31, 2019 | 18.95 Mn |
| Dec 31, 2018 | 17.87 Mn |
| Sep 30, 2018 | 18.95 Mn |
| Jun 30, 2018 | 18.95 Mn |
| Mar 31, 2018 | 14.52 Mn |
| Dec 31, 2017 | 6.29 Mn |
| Dec 31, 2016 | 6.29 Mn |